Clinical potential of SLAMF7 antibodies – focus on elotuzumab in multiple myeloma

• Main Authors: Friend R (Author), Bhutani M (Author), Voorhees PM (Author), Usmani SZ (Author)
• Format: Book
• Published: Dove Medical Press, 2017-03-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Summary

Reed Friend, Manisha Bhutani, Peter M Voorhees, Saad Z Usmani Department of Hematologic Oncology & Blood Disorders, Levine Cancer Institute, Carolinas Healthcare System, UNC School of Medicine, Charlotte, NC, USA Abstract: Elotuzumab is one of the first monoclonal antibodies to be approved for the treatment of multiple myeloma. It is a humanized immunoglobulin G kappa (IgGκ) antibody that targets signaling lymphocytic activation molecule family member 7 (SLAMF7), a surface marker that is highly expressed on normal and malignant plasma cells. This review summarizes the preclinical and clinical data that led to the approval of elotuzumab, along with a discussion on the ongoing and future clinical investigations. Keywords: multiple myeloma, relapsed, refractory, treatment, elotuzumab, SLAMF7, CS1

Item Description

1177-8881